Publish lobbying messages from pharma, UK PM told

26 April 2021

A cross-party group of members of parliament (MPs) and peers in the UK have signed a joint statement with patient advocacy organizations calling for Prime Minister Boris Johnson, ministers and senior civil servants to publish email, text and WhatsApp messages exchanged with pharma companies and their lobbyists.

Signatories want to know if private lobbying has influenced the UK’s opposition to a waiver of intellectual property (IP) rules for COVID-19 vaccines at the World Trade Organization (WTO).

Patient advocacy and vaccine equity organizations that have signed the statement include Global Justice Now, Just Treatment, StopAIDS, Frontline AIDS, Universities Allied for Essential Medicines UK, Students for Global Health, and Nurses United UK.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK